Financials data is unavailable for this security.
View more
Year on year Clinuvel Pharmaceuticals Ltd grew revenues 16.15% from 82.23m to 95.50m while net income improved 16.44% from 30.60m to 35.64m.
Gross margin | 101.16% |
---|---|
Net profit margin | 37.31% |
Operating margin | 58.53% |
Return on assets | 16.78% |
---|---|
Return on equity | 19.39% |
Return on investment | 19.05% |
More ▼
Cash flow in AUDView more
In 2024, Clinuvel Pharmaceuticals Ltd increased its cash reserves by 10.37%, or 3.31m. The company earned 37.05m from its operations for a Cash Flow Margin of 38.80%. In addition the company used 29.03m on investing activities and also paid 3.57m in financing cash flows.
Cash flow per share | 0.7208 |
---|---|
Price/Cash flow per share | 18.65 |
Book value per share | 4.05 |
---|---|
Tangible book value per share | 4.05 |
More ▼
Balance sheet in AUDView more
Current ratio | 8.81 |
---|---|
Quick ratio | 8.39 |
Total debt/total equity | 0.0043 |
---|---|
Total debt/total capital | 0.0043 |
More ▼
Growth rates in AUD
SmartText is unavailable
Div yield(5 year avg) | 0.18% |
---|---|
Div growth rate (5 year) | 14.87% |
Payout ratio (TTM) | 0.00% |
EPS growth(5 years) | 13.82 |
---|---|
EPS (TTM) vs TTM 1 year ago | 18.79 |
More ▼